Antibody targeted drugs as cancer therapeutics (Q36373103)

13 August 2017

1 reference

title

Antibody targeted drugs as cancer therapeutics (English)

1 reference

13 August 2017

1 reference

3

Jürgen C Becker

1 reference

13 August 2017

David Schrama

1

1 reference

PubMed ID

16424916

13 August 2017

Ralph A Reisfeld

series ordinal

2

1 reference

13 August 2017

1 February 2006

1 reference

Nature Reviews Drug Discovery

13 August 2017

1 reference

13 August 2017

5

1 reference

13 August 2017

2

1 reference

13 August 2017

147-159

1 reference

https://scigraph.springernature.com/pub.10.1038/nrd1957

13 August 2017

0 references

cites work

A vindesine-anti-CEA conjugate cytotoxic for human cancer cells in vitro

1 reference

Antibody directed enzymes revive anti-cancer prodrugs concept

21 January 2018

1 reference

Recombinant anti-human HER2/neu IgG3-(GM-CSF) fusion protein retains antigen specificity and cytokine function and demonstrates antitumor activity

21 January 2018

1 reference

Synergistic antitumor effect of bispecific CD19 x CD3 and CD19 x CD16 diabodies in a preclinical model of non-Hodgkin's lymphoma

21 January 2018

1 reference

A new recombinant single chain trispecific antibody recruits T lymphocytes to kill CEA (carcinoma embryonic antigen) positive tumor cells in vitro efficiently

21 January 2018

1 reference

Shift from systemic to site-specific memory by tumor-targeted IL-2.

21 January 2018

1 reference

National Cancer Act: leaders reflect on 30 years of progress

21 January 2018

1 reference

Paul Ehrlich's magic bullets

31 March 2020

1 reference

Monoclonal antibodies: a powerful new tool in biology and medicine

31 March 2020

1 reference

Reshaping human antibodies for therapy

31 March 2020

1 reference

Chimeric mouse-human IgG1 antibody that can mediate lysis of cancer cells

31 March 2020

1 reference

Rituximab: ongoing and future clinical development

31 March 2020

1 reference

Therapeutic monoclonal antibodies

31 March 2020

1 reference

Monoclonal antibody therapy of cancer

31 March 2020

1 reference

Antibody-targeted radiation cancer therapy

31 March 2020

1 reference

Targeted drug conjugates: principles and progress

31 March 2020

1 reference

31 March 2020

1 reference

Prodrug chemotherapeutics bypass p-glycoprotein resistance and kill tumors in vivo with high efficacy and target-dependent selectivity.

31 March 2020

1 reference

Development of potent monoclonal antibody auristatin conjugates for cancer therapy

31 March 2020

1 reference

Recent advances in tumor-targeting anticancer drug conjugates.

31 March 2020

1 reference

Ligand-targeted therapeutics in anticancer therapy

31 March 2020

1 reference

Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate

31 March 2020

1 reference

Improving the efficacy of antibody-based cancer therapies

31 March 2020

1 reference

Mylotarg: antibody-targeted chemotherapy comes of age.

31 March 2020

1 reference

Phase II pilot trial of gemtuzumab ozogamicin (GO) as first line therapy in acute myeloid leukemia patients age 65 or older

31 March 2020

1 reference

Drug therapy for acute myeloid leukemia

31 March 2020

1 reference

Safety and efficacy of gemtuzumab ozogamicin in pediatric patients with advanced CD33+ acute myeloid leukemia.

31 March 2020

1 reference

Synthesis and biological evaluation of novel taxoids designed for targeted delivery to tumors

31 March 2020

1 reference

Herceptin-geldanamycin immunoconjugates: pharmacokinetics, biodistribution, and enhanced antitumor activity

31 March 2020

1 reference

New anti-T cell immunotoxins for the clinic

31 March 2020

1 reference

Influence of relative binding affinity on efficacy in a panel of anti-CD3 scFv immunotoxins

31 March 2020

1 reference

Reducing the immune response to immunotoxin

31 March 2020

1 reference

Carbohydrate-specifically polyethylene glycol-modified ricin A-chain with improved therapeutic potential

31 March 2020

1 reference

A dimeric angiogenin immunofusion protein mediates selective toxicity toward CD22+ tumor cells.

31 March 2020

1 reference

Targeting malignant B-cell lymphoma with a humanized anti-CD22 scFv-angiogenin immunoenzyme.

31 March 2020

1 reference

A fully human antitumor immunoRNase selective for ErbB-2-positive carcinomas.

31 March 2020

1 reference

Eradication of large colon tumor xenografts by targeted delivery of maytansinoids

31 March 2020

1 reference

Tumor-activated prodrugs--a new approach to cancer therapy

31 March 2020

1 reference

Engineering antibodies for clinical applications in cancer

31 March 2020

1 reference

Selective activation of anticancer prodrugs by monoclonal antibody-enzyme conjugates

31 March 2020

1 reference

Protection against a nonimmunogenic mouse leukemia by an immunogenic variant obtained by mutagenesis

31 March 2020

1 reference

Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating response

31 March 2020

1 reference

Cytokine gene therapy or infusion as treatment for solid human cancer.

31 March 2020

1 reference

Tumor necrosis factor-alpha in isolated perfusion systems in the treatment of cancer: the Rotterdam preclinical-clinical program

31 March 2020

1 reference

IL-12 deaths: explanation and a puzzle

31 March 2020

1 reference

Intratumoral PEG-interleukin-2 therapy in patients with locoregionally recurrent head and neck squamous-cell carcinoma

31 March 2020

1 reference

High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma

31 March 2020

1 reference

Construction and expression of antibody-tumor necrosis factor fusion proteins

31 March 2020

1 reference

Expression of genetically engineered immunoconjugates of lymphotoxin and a chimeric anti-ganglioside GD2 antibody

31 March 2020

1 reference

Biological activity and in vivo clearance of antitumor antibody/cytokine fusion proteins

31 March 2020

1 reference

Eradication of established hepatic human neuroblastoma metastases in mice with severe combined immunodeficiency by antibody-targeted interleukin-2

31 March 2020

1 reference

Eradication of human hepatic and pulmonary melanoma metastases in SCID mice by antibody-interleukin 2 fusion proteins

31 March 2020

1 reference

Pharmacokinetics and stability of the ch14.18-interleukin-2 fusion protein in mice

31 March 2020

1 reference

T cell-mediated eradication of murine metastatic melanoma induced by targeted interleukin 2 therapy

31 March 2020

1 reference

Protein vaccination with the HER2/neu extracellular domain plus anti-HER2/neu antibody-cytokine fusion proteins induces a protective anti-HER2/neu immune response in mice

31 March 2020

1 reference

Phase I clinical trial of the immunocytokine EMD 273063 in melanoma patients

31 March 2020

1 reference

Safety, pharmacokinetics, and biological pharmacodynamics of the immunocytokine EMD 273066 (huKS-IL2): results of a phase I trial in patients with prostate cancer.

31 March 2020

1 reference

Antidisialoganglioside/granulocyte macrophage-colony-stimulating factor fusion protein facilitates neutrophil antibody-dependent cellular cytotoxicity and depends on FcgammaRII (CD32) and Mac-1 (CD11b/CD18) for enhanced effector cell adhesion and az

31 March 2020

1 reference

Selective targeted delivery of TNFalpha to tumor blood vessels.

31 March 2020

1 reference

Engineered vascular-targeting antibody-interferon-γ fusion protein for cancer therapy

31 March 2020

1 reference

Engineered antibody fragments and the rise of single domains

31 March 2020

1 reference

Targeting of lymphotoxin-alpha to the tumor elicits an efficient immune response associated with induction of peripheral lymphoid-like tissue

31 March 2020

1 reference

Simultaneous targeting of IL2 and IL12 to Hodgkin's lymphoma cells enhances activation of resting NK cells and tumor cell lysis

31 March 2020

1 reference

A trial to kill tumor cells through Fas (CD95)-mediated apoptosis in vivo

31 March 2020

1 reference

Fas receptor-mediated apoptosis: a clinical application?

31 March 2020

1 reference

Conversion of membrane-bound Fas(CD95) ligand to its soluble form is associated with downregulation of its proapoptotic activity and loss of liver toxicity

31 March 2020

1 reference

Generation of a FasL-based proapoptotic fusion protein devoid of systemic toxicity due to cell-surface antigen-restricted Activation

31 March 2020

1 reference

Target cell-restricted apoptosis induction of acute leukemic T cells by a recombinant tumor necrosis factor-related apoptosis-inducing ligand fusion protein with specificity for human CD7.

31 March 2020

1 reference

Simultaneous inhibition of epidermal growth factor receptor (EGFR) signaling and enhanced activation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) receptor-mediated apoptosis induction by an scFv:sTRAIL fusion protein with speci

31 March 2020

1 reference

Antitumor effects of radioiodinated antisense oligonuclide mediated by VIP receptor

31 March 2020

1 reference

Neuroblastoma targeting by c-myb-selective antisense oligonucleotides entrapped in anti-GD2 immunoliposome: immune cell-mediated anti-tumor activities.

31 March 2020

1 reference

Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle

31 March 2020

1 reference

Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors

31 March 2020

1 reference

A recombinant bispecific single-chain antibody induces targeted, supra-agonistic CD28-stimulation and tumor cell killing

31 March 2020

1 reference

Bispecific CD3 x CD19 diabody for T cell-mediated lysis of malignant human B cells.

31 March 2020

1 reference

Effective lysis of lymphoma cells with a stabilised bispecific single-chain Fv antibody against CD19 and FcgammaRIII (CD16)

31 March 2020

1 reference

Efficient inhibition of multidrug-resistant human tumors with a recombinant bispecific anti-P-glycoprotein x anti-CD3 diabody.

31 March 2020

1 reference

BiTEs: bispecific antibody constructs with unique anti-tumor activity

31 March 2020

1 reference

Monoclonal antibodies as therapeutic agents for cancer

31 March 2020

1 reference

Making antibodies by phage display technology

31 March 2020

1 reference

Tumour vascular targeting

31 March 2020

1 reference

Subtractive proteomic mapping of the endothelial surface in lung and solid tumours for tissue-specific therapy

31 March 2020

1 reference

Antibody-targeted interleukin 2 stimulates T-cell killing of autologous tumor cells

31 March 2020

1 reference

Activation of preexisting T cell clones by targeted interleukin 2 therapy

31 March 2020

1 reference

Melanoma immunotherapy by targeted IL-2 depends on CD4(+) T-cell help mediated by CD40/CD40L interaction

31 March 2020

1 reference

Enhanced activity of hu14.18-IL2 immunocytokine against murine NXS2 neuroblastoma when combined with interleukin 2 therapy

31 March 2020

1 reference

Specific peptide-mediated immunity against established melanoma tumors with dendritic cells requires IL-2 and fetal calf serum-free cell culture

31 March 2020

1 reference

An IgG3-IL-2 fusion protein recognizing a murine B cell lymphoma exhibits effective tumor imaging and antitumor activity

31 March 2020

1 reference

Arming antibodies: prospects and challenges for immunoconjugates

31 March 2020

1 reference

A phase I trial of antibody directed enzyme prodrug therapy (ADEPT) in patients with advanced colorectal carcinoma or other CEA producing tumours

31 March 2020

1 reference

Insights into the mechanism of anti-tumor immunity in mice vaccinated with the human HER2/neu extracellular domain plus anti-HER2/neu IgG3-(IL-2) or anti-HER2/neu IgG3-(GM-CSF) fusion protein

31 March 2020

1 reference

inferred from DOI database lookup

7 January 2021

based on heuristic

Tumor stroma-associated antigens for anti-cancer immunotherapy

1 reference

inferred from DOI database lookup

7 January 2021

based on heuristic

Therapeutic efficacy of tumor-targeted IL2 in LTalpha(-/-) mice depends on conditioned T cells.

1 reference

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/NRD1957

1 reference

13 August 2017

1 reference

PubMed ID

16424916